AC Immune (ACIU) stock shot up 20% Thursday after the company reported positive data from a Phase 2 study of its drug ...

There has been a lot of excitement since the launch. Not only is the drug extremely effective (people lose about 15 percent ...

AC Immune SA (ACIU) has released an update. AC Immune SA announced promising interim results from its Phase 2 trial of the ACI-7104.056 ...

With rising demand and an ageing population, European healthcare systems are under strain. In the second article in our ...

reinforces the best-in-class characteristics of our clinically validated anti-a-syn active immunotherapy for the treatment of ...

AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein ...

Researchers are using functionalized nanodiamonds to precisely monitor neuronal activity at the cellular level, enhancing ...

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN) ...

The weight-loss jab Wegovy made its debut on June 4 2021 . It was the first new weight-loss drug to be approved by the US ...

Transformative Financing worth up to $275 million from Top-Tier Institutional Healthcare Investors -- -- Advancement of IkT-001Pro into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypert ...

Dementia is a debilitating neurodegenerative disease that gradually diminishes life quality, leading to memory loss, ...

The connection between auditory or vestibular disorders and neuroinflammatory or neurodegenerative diseases has gained ...